bevacizumab + valproic acid

Bevacizumab + valproic acid is an investigational combination therapy comprising two distinct agents with complementary mechanisms of action. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and restricting tumor blood supply. Valproic acid, primarily known as an antiepileptic drug, also acts as a histone deacetylase inhibitor (HDACi), modulating gene expression and promoting differentiation, apoptosis, and sensitization of cancer cells to chemotherapy. This combination has been studied in clinical trials for advanced malignancies—including metastatic colorectal cancer—based on preclinical evidence suggesting synergistic anticancer effects through anti-angiogenic and epigenetic modulation pathways[3][4]. The regimen is being evaluated for its ability to improve progression-free survival when added to standard chemotherapy regimens.